Clinical Trial Update: Mesalamine to Reduce T Cell Activation in HIV Infection [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating mesalamine for reducing T cell activation in HIV infection has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Human Immunodeficiency Virus Infection

Drugs mentioned

• Mesalamine (Mesalamine)

Snippet

Sponsor: University of California, San Francisco | Conditions: HIV Infections, Sexually Transmitted Diseases | Phase 4 | Status: COMPLETED | Results posted: 2014-08-11